Emerging roles of sortilin in affecting the metabolism of glucose and lipid profiles

Xin Su*, Linjian Chen*, Xiang Chen, Cuilian Dai*, Bin Wang*

ABSTRACT

Dyslipidemia has recently been identified as an important factor in modulating the progression of several health conditions, grouped as cardiometabolic syndrome and including obesity, insulin resistance, and atherosclerosis. Among multiple factors which regulate the development of cardiometabolic syndrome, sortilin has been found in multiple cell types, such as adipocyte, hepatocyte, and macrophage, suggesting that sortilin is correlated to the development and the severity of cardiometabolic syndrome. Consistently, several genome-wide association studies and basic experimental research studies are being conducted to find novel gene loci involved in regulating the pathological progression of cardiometabolic syndrome. According to these data, both sortilin 1 gene and sortilin protein have an important function in regulating the circulating lipid and glucose metabolism resulting in modulation of disease progression. In this comprehensive review, we summarize the recent research results regarding sortilin function in modulating the circulating lipid and glucose metabolism. Moreover, we also discuss and analyze the emerging evidence elucidating the potential mechanisms by which sortilin affect synthesis and secretion of lipid and glucose.

KEYWORDS: Sortilin; dyslipidemia; insulin resistance; diabetes mellitus; cardiovascular disease

INTRODUCTION

According to the eye-catching reports worldwide, dyslipidemia has been demonstrated as one of the most essential factors which is strongly associated with the pathological development of several health problems, such as hypertension, overweight/obesity, diabetes mellitus, and atherosclerotic related cardiovascular diseases, which are currently given a conception as cardiometabolic syndrome [1]. Actually, due to the results of epidemiological studies, dyslipidemia has become one of the most pressing issues worldwide during the past several decades, posing serious threat to human health and promoting a high mortality [2]. In addition, it is also worth noting that dyslipidemia, characterized by elevated serum concentrations of low-density lipoprotein cholesterol (LDL-C), very LDL-C (VLDL-C), and decreased serum concentrations of high-density lipoprotein cholesterol, has also been considered as the most vital modifiable factor hand in hand with the development and the severity of cardiometabolic syndrome [3]. In details, it has been demonstrated that the progression of LDL particle intruding into sub-endothelium within circulation induced by the macrophage is intimately involved in the pathogenesis of atherosclerotic related cardiovascular diseases; by contrast, the lower serum concentrations of LDL-C induced using lipid-lowering agents, such as statins or Ezetimibe, are closely associated with the inhibition of atherosclerotic lesions which further reduced the risk and suppressed the severity of cardiometabolic syndromes [4].

As is known to us, several metabolic related cell types, such as the adipocyte, the macrophage, and the hepatocyte, have been confirmed as the crucial cells participating in circulating lipid metabolism. On the other hand, increasing evidence has put forward that several lipid metabolic related genes, such as low density lipoprotein receptor (LDLR) gene and proprotein convertase subtilisin/kexin type 9 (PCSK9) gene, embrace a vital function in regulating circulating and intracellular levels of lipid profiles [5-7]. Noteworthy, multiple genetic studies revealed that the progression of atherosclerosis was strongly heritable, since the variations characterized by significantly elevated serum concentrations LDL-C in those genes. Further understanding of the correlation between the mutations of lipid metabolic related genes with the pathology of atherosclerosis could put forward an efficient treatment strategy to inhibit the process of cardiometabolic disorders [8]. Although the investigations of rare Mendelian disorders with the serum concentrations LDL-C provide a novel insight of the modulatory genetics on lipid metabolism [9], the disorders could...
not explain the various risks of dyslipidemia and its related metabolic diseases in general populations, suggesting that there might be other undiscovered gene which holds essential role in the variability of lipid profiles.

During the recent past decades, the genome wide association studies (GWAS) have given multiple new gene loci which are involved in circulating lipid catabolism. Notably, among these gene loci, the chromosome 1p13 has recently been demonstrated to embrace an important role in modulating the metabolism of lipid and glucose. According to the reports, this loci harbored multiple metabolic related genes, including cadherin EGF LAG seven-pass G-type receptor 2 gene, proline-serine-rich-coiled protein 1 gene, and sortilin 1 (SORT1) gene [10]. Among those three genes, the single gene polymorphisms single nucleotide polymorphisms (SNP) of SORT1 gene in linking dyslipidemia and the pathogenesis of cardiometabolic syndrome has been published by several large-scale studies [11,12]. Besides, as a family member of a larger vacuolar protein sorting 10 protein (Vps10p) family, sortilin embraces the capability in binding to diverse ligands within different cells [13]. In the present comprehensive review, the understanding of sortilin in regulating circulating or intracellular lipid metabolism has been summarized. In addition, the mechanisms whereby sortilin regulates the metabolic progression of lipid and glucose in adipocyte, hepatocyte, and macrophage are also proposed for elucidating the biological function of sortilin.

BASIC FEATURES OF SORT1 GENE AND SORTILIN PROTEIN

As mentioned above, sortilin belongs to the protein family of Vps10p receptors. Emerging evidence provided by computational and functional proteomics research has demonstrated that there is a 700 amino-acid in the N-terminus of domain of Vps10p (Vps10p-D), which could further combine to ligands site and mediate the intracellular transportation of synthesized protein between trans-Golgi network (TGN) and endosomes [14,15]. Thereby, Vps10p has been identified as a novel type-1 trans-membrane protein that is mainly found on the membrane [16]. Aside from sortilin, the Vps10p family protein also contains four other members, as sorting protein-related receptor with A-type repeats and sortilin-related receptor central nervous system (CNS) expressed 1-3 [17]. Notably, sortilin is considered as the first discovered non-G-protein-coupled receptor in mammals.

On the other hand, results from the protein crystallization research revealed that the precursor of sortilin contained a relatively long N-terminal peptide and a relatively short C-terminal cytoplasmic tail which could combine with the receptor on the surface of Golgi [18]. The mature sortilin, as a 95 kDa peptide chain with 874 amino acids, is majorly localized on the TGN. Nevertheless, a minor fraction of mature sortilin could be found on the membrane. After combining to a ligand, the mature sortilin could form a β-propeller structure that contains several binding sites [19].

Sortilin has firstly been found to be abundant within the CNS and been described as a neurotransmitter receptor which regulates neuronal cells survival and death; however, it has recently been found in multiple cell types, such as adipocyte, hepatocyte, and macrophage [20]. At cellular level, sortilin acts as a linking protein between the TGN, endosome, lysosome, and induces multiple lipoprotein including lipoprotein lipase (LPL), apolipoprotein E (Apo-E), and Apo-Broo [21]. Otherwise, at membrane level, sortilin acts as an uptake receptor which mediates the endocytosis progression of native LDL by the macrophage [22]. Furthermore, the trafficking properties of sortilin were demonstrated to take part in protein cargo sorting [23]. Concerning this notion, several ligands of sortilin, such as Apo-Broo, could be transported from endosome to Golgi apparatus. Other ligands, such as Apo-E, are targeted on lysosomal degradation [24]. Conclusively, the findings demonstrated above indicate that sortilin is importantly correlated to the pathologic development and the severity of cardiometabolic syndrome.

ROLE OF SORTILIN IN MODULATING LIPID METABOLISM

Since it has been proposed that sortilin is correlated with cardio-metabolic disorder diseases, the current focus is transferring to elucidating the important effect of sortilin as well as exploring mechanisms by which SORT1 gene or sortilin protein affects the risk of dyslipidemia [25]. Emerging evidence provided by diverse research suggests that sortilin has been identified as a new modulator of intracellular or serum lipid metabolism. The summary of sortilin in modulating lipid metabolism was listed in Table 1.

SORT1 SNPs IN LIPID METABOLISM

At present, extensive sequencing analysis of human SORT1 gene interval is being conducted to identify SNPs of SORT1 gene by GWAS. As shown, a close relationship between SORT1 gene SNPs with circulating levels of serum lipid profiles has been put forward by different research from diverse countries. For instance, the first research, which found the relationship between SORT1 gene SNPs and the risk of dyslipidemia, used data of approximately 9,000 patients and discovered that SNPs of 18 gene loci had relationship with alterations of serum lipid profiles. Among these loci, the 1p13 locus was shown to be correlated with the SORT1 gene, and a proxy for 1p13 locus SNP was afterward confirmed to influence the
development of atherosclerotic cardiovascular diseases [11]. Likewise, Schadt et al. also identified SORT1 gene SNP had a close relationship with the altered serum LDL-C [26]. Results from GWAS of the Third United States National Health and Nutrition Examination Survey also provided the similar relationship, demonstrating that the SORT1 gene SNP play embraces a significant function in modulating serum lipid profile [27].

Due to the basic experimental advances, multiple eye-catching breakthroughs have been made to explain several novel SORT1 gene SNPs, such as rs646776 SNP, rs12734074 SNP, and rs623901 SNP, and serum lipid and glucose levels. Recently, with in-depth investigations, Nakayama et al. enrolled more than 21,000 Japanese subjects and demonstrated that the rs599839 SNP was correlated with significantly decreased circulating concentrations of atherogenic related lipid profiles, including TG and LDL-C [28]. In addition, these results have also been replicated in diverse investigations from several European countries, indicating that the G-allele within rs599839 SNP was positively associated with the risk and the development of atherosclerotic cardiovascular diseases [29,30].

On the other hand, a study revealed that rs12740374 SNP was strongly correlated with circulating levels of LDL-C [31]. Similar with this finding, Musunuru et al. also put forward that the rs12740374 SNP promoted the expression levels of CCAAT/enhancer binding protein (C/EBP) within hepatocyte, inducing to the lower concentrations of LDL-C and tge suppressed production of VLDL particles [32]. Besides, this result also suggests that SORT1 gene SNP regulates the risk of dyslipidemia potentially through, at least partly, regulating the gene expression content of C/EBP.

Recently, the rs646776 SNP was also identified to be correlated with elevated circulating concentrations of LDL-C in children and youth [33]. Aside from the modulatory role in serum LDL-C, the rs646776 SNP also presented a genotype-specific discordance in serum LDL-C concentrations which was greater within younger participants compared to those within the older participants [34]. Consistent relationship was further found in numerous research which focuses on participants from diverse countries [35-38]. By summarizing the results of these researches, Zeng et al. focused on the correlation between rs646776 SNP with circulating lipid levels in the Chinese Han population. Interestingly, the authors confirmed that the rs646776 SNP could up-regulate the SORT1 gene expression and as a consequence, increase the circulating LDL-C levels [39]. More recently, another study enrolled a cohort of 2,800 African-Americans and observed that a novel SORT1 gene SNP, named rs629301 SNP, was associated with the plasma concentrations of LDL-C and VLDL-C [40]. Taken together, these results indicate that several SORT1 gene SNPs hold a genetic link between serum lipid hemostasis with the pathogenesis of cardiometabolic syndrome, including obesity, hypertension, and the atherosclerotic related coronary artery disease.

**SORTILIN IN LIPID METABOLISM**

**IN VITRO**

According to the findings from several in vitro researches, a direct relationship between sortilin and lipid metabolism is well-established using diverse cell types [41-43]. For instance, Patel et al. used the macrophages that were derived from the bone marrow of SORT1-deficient mice and found that these macrophages had significantly reduced uptake rate of LDL-C which subsequently led to an inhibition of foam cells formation. On the contrary, over-expressed SORT1 gene within macrophage induced up-regulated LDL uptake, indicating that increased SORT1 gene expression within macrophage could lead to increased intercellular lipid storage [44].

Besides the important function of sortilin in macrophage, other research used HEK293 cells and found that sortilin led to increased total cholesterol levels within circulation. Jkobly et al. and Gustafsen et al. found that sortilin could co-localize with PCSK9 in the TNG, thus enhance the secretion of PCSK9 from HEK293 cells, inducing a degradation of LDL receptor and a reduced clearance rate of LDL-C [45,46]. Further, study by Linsel-Nitschke et al. also revealed that over-expression of SORT1 gene resulted in increased endocytosis of LDL-C rate within HEK293 cells [47].

Eye-catchingly, a recent research demonstrated that the primary hepatocyte isolated from SORT1 gene-knockout mice exhibited significantly reduced LDL-C contents compared with those within wide-type (WT) mice. With in-depth research, the authors found the expression levels of lipogenic related genes, including fatty acid binding protein-4 (FABP-4) gene and stearoyl-CoA desaturase-1 gene, were down-regulated remarkably within the hepatocytes isolated from SORT1 gene-knockout mice, proposing a potential pathway by which sortilin influences the intracellular lipid concentration within the hepatocyte [48].

The important function of sortilin in modulating intracellular lipid metabolism in other cell types has also begun to gain appreciation. Noteworthy, Strong et al. provided evidence that over-expression of SORT1 gene in diverse cell lines could induce an increase in LDL clearance [15,42]. In addition, Tveten transfected plasmids, which contained WT SORT1 gene or mutant SORT1 gene, in HeLa TREx cells and demonstrated a positive relationship between the contents of sortilin on the cell surface and the concentrations of LDL bound, revealing that sortilin could not elevate the binding of LDL through an intracellular potential mechanism whereas
on the cell surface [49]. In conclusion, these results revealed a functional role linking expression of SORT1 gene and sortilin protein with intracellular lipid levels.

SORTILIN IN LIPID METABOLISM IN VIVO

It is worth noting that several reports cumulatively revealed that knockout of SORT1 gene reduced the serum lipid levels and the atherosclerotic plaque area significantly. Patel et al. observed a significant reduction of atherosclerosis in LDLR (-/-) mice with transplanted SORT1(-/-) bone marrow, without an effect on the serum concentrations LDL-C [44]. Furthermore, lack of SORT1 expression leads to a robust drop of LDL-C and total cholesterol within circulation, however, the hepatocyte-specific over-expression of SORT1 gene induced the significantly increased concentrations of LDL-C and TG [44]. Consistent results were presented in several basic experimental studies, conducted by Rabinowich et al. and Kjolby et al., which showed decreased circulating levels of intermediate density lipoprotein in SORT1-knockout mice and in SORT1/LDLR-double knockout (DKO) mice [12,45-48]. In addition, the mice with LDLR-deficiency and over-expressed the SORT1 gene also displayed increased sortilin protein expression and accelerated circulating LDL-C clearance. Simultaneously, when SORT1(-/-) mice were treated intravenously with tyloapol, a special inhibitor of LPL, the VLDL particles were smaller than that in WT mice [12]. Using SORT1(-/-) mice on a chow diet, Strong et al. found that SORT1 deficiency had a close relationship with reduced VLDL production and increased LDL catabolism [15,42]. Consistently, Mortensen et al. reported that SORT1/APOE-DKO mice displayed slightly lower cholesterol levels than that in APOE(-/-) mice with SORT1 over-expression [50]. More recently, Hagita et al. showed that in the LDLR(-/-) mice model, SORT1 deficiency could lead to a reduction in body weight and in plasma TG levels, indicating that SORT1 could influence the development of obesity [51].

Importantly, several studies concerned the relationship between the levels of sortilin and lipid in clinical patients. Ogawa et al. reported that in aspirin-treated CAD patients, the platelet aggregation could induce solute sortilin release, which could be suppressed by aspirin. In addition, plasma solute sortilin was higher in patients with hypertension, dyslipidemia and diabetes without coronary artery disease than in patients with coronary artery disease who underwent the aspirin therapy. In these patients, the levels of circulating solute sortilin hold positive relationship with circulating levels of LDL-C and TG [52]. In 2017, Hu et al. demonstrated that serum levels of PCSK9 and sortilin were significantly up-regulated in patients with coronary artery disease. Furthermore, the PCSK9 was independent related to the expression levels of sortilin, indicating that sortilin could mediate the secretion of PCSK9 in plasma [53]. As firmly reported, PCSK9 induces reduced LDL-C clearance within circulation through the degradation of LDLR, we could speculate that sortilin may facilitate the risk of atherosclerotic related diseases through the expression of PCSK9.

MECHANISMS OF SORTILIN IN INTRACELLULAR LIPID METABOLISM

Hepatocyte

As described previously, hepatocytes produce and release multiple proteins which embrace an eye-catching role in regulating lipid metabolism. Thus, hepatocyte is considered as a key factor in the risk of dyslipidemia [54]. Under the condition of hepatic related diseases, such as the non-alcoholic fatty liver diseases, the metabolic processes of serum lipid profiles are impaired owing to the aberrant lipid metabolism by hepatocyte [55,56]. In addition, under that pathological condition, excessive circulating lipid profiles may enter into hepatocytes, which subsequently cause excessive intracellular lipid load [57]. However, the accurate mechanisms whereby sortilin influences the intracellular lipid catabolism in hepatocytes need to be further elucidated.

Actually, several underlying mechanisms have been provided to further explain the association between sortilin with the risk and the development of dyslipidemia. First, as described, LDL-C is produced by VLDL through lipolysis. Therefore, the major mechanism is that SORT1 gene in hepatocyte may promote VLDL lipolysis by interacting with ApoB-100 and as a consequence, increases circulating LDL-C level. These findings indicate that sortilin combines Apo-B100 within Golgi apparatus and resultantly regulates the formation of VLDL within hepatocyte and LDL within circulation [43]. Second, sortilin has been found to interact with PCSK9; additionally, sortilin promotes PCSK9 production and secretion in hepatocytes. Notably, the up-regulated PCSK9 could bind to LDLR and trigger the degradation process of LDLR, which could induce a significant reduction of LDL-C clearance within circulation [46,58]. Third, it is also worth paid attention that the mice with SORT1-deficiency also present a decreased released rate of VLDL, accompanied with the reduction of circulating concentrations of LDL-C. Recently, an independent research demonstrated that the hepatocyte isolated from the mice with SORT1-deficiency presented the decreased risk of diet-induced hepatic steatosis. After intervening mice with AF38469, as an orally bioactive inhibitor of sortilin, the authors demonstrated that these mice displayed reduced circulating concentrations of LDL-C and relatively lower expression
levels of pro-inflammatory cytokines within hepatocytes. Synchronously, AF38469 intervention has also been reported to be correlated with lower hepatic VLDL released and higher expression levels of cholesterol 7α-hydroxase [59].

**TABLE 1.** Summary of sortilin in modulating lipid metabolism

| Model                      | Sample Source  | Manipulation     | Diet       | Sortilin expression | Plasma cholesterol | Intracellular cholesterol | Apolipoprotein secretion | LDL clearance | Reference       |
|----------------------------|----------------|------------------|------------|---------------------|--------------------|--------------------------|--------------------------|---------------|-----------------|
| **Genome wide association study** |                |                  |            |                     |                    |                          |                          |               |                 |
| rs59839                    | Human          | N/A              | N/A        | ↓                   | ↓                  | –                        | –                        | –             | [28,29,30]     |
| rs646776                   | Human          | N/A              | N/A        | ↑                   | ↑                  | –                        | –                        | –             | [33-36]        |
| rs12740374                 | Human          | N/A              | N/A        | ↓                   | ↓                  | –                        | –                        | –             | [31,32]        |
| rs629304                   | Human          | N/A              | N/A        | ↓                   | ↓                  | –                        | –                        | –             | [40]            |
| **In vitro research**      |                |                  |            |                     |                    |                          |                          |               |                 |
| CHO Cells                  | Chinese hamster ovary | Over-expressed SORT1 gene | –          | ↑                   | –                  | ↑                        | –                        | ↑             | [42]            |
| HEK293 Cells               | Human embryonic kidney | Over-expressed SORT1 gene | –          | ↑                   | –                  | ↑                        | –                        | ↑             | [43,44]        |
| HuH7 Cells                 | Human hepatoma  | Over-expressed SORT1 gene | –          | ↑                   | –                  | ↑                        | ↓                        | ↑             | [45]            |
| HELA-TREx Cells            | Human cervical cancer | Over-expressed SORT1 gene | –          | ↑                   | –                  | ↑                        | –                        | ↑             | [48]            |
| HepG2 Cells                | Human hepatoma  | Over-expressed SORT1 gene | –          | ↑                   | –                  | ↑                        | ↓                        | –             | [50,51]        |
| IdlD Cells                 | Chinese hamster ovary | Over-expressed SORT1 gene | –          | ↑                   | –                  | ↑                        | –                        | ↑             | [32]            |
| McA Cells                  | Mice           | Over-expressed SORT1 gene | –          | ↑                   | –                  | ↑                        | –                        | ↑             | [33]            |
| Primary Hepatocytes        | Mice liver     | Over-expressed SORT1 gene | –          | ↑                   | –                  | ↑                        | –                        | ↑             | [20-22]        |
| **In vivo research**       |                |                  |            |                     |                    |                          |                          |               |                 |
| APOBEC1-/-; LDLR/-/-       | Mice           | Over-expressed SORT1 gene | Chow       | ↑                   | ↑                  | –                        | –                        | –             | [51]            |
| APOBEC1-/-; hAPOB Tg       | Mice           | Over-expressed SORT1 gene | Chow       | ↑                   | ↑                  | –                        | ↓                        | –             | [52-54]        |
| APOBEC1-/-; LDLR+/-; hAPOB Tg | Mice          | Over-expressed SORT1 gene | Chow       | ↑                   | ↑                  | –                        | ↓                        | –             | [55]            |
| APOBEC1-/-; LDLR-/-; hAPOB Tg | Mice         | Over-expressed SORT1 gene | Chow       | ↑                   | ↑                  | –                        | –                        | –             | [39,58,59]     |
| WT                         | Mice           | Over-expressed SORT1 gene | HCD        | ↑                   | ↑                  | –                        | –                        | –             | [29]            |
| SORT1-/-; LDLR/-/-         | Mice           | Over-expressed SORT1 gene | HCD        | ↑                   | ↑                  | –                        | –                        | –             | [15,43,44,48-51] |
| APOBEC1-/-; LDLR/-/-       | Mice           | Knockout of SORT1 gene | Chow       | ↓                   | ↓                  | –                        | –                        | –             | [52]            |
| APOBEC1-/-; hAPOB Tg       | Mice           | Knockout of SORT1 gene | Chow       | ↓                   | ↓                  | –                        | –                        | –             | [54]            |
| APOBEC1-/-; LDLR+/-; hAPOB Tg | Mice          | Knockout of SORT1 gene | Chow       | ↓                   | ↓                  | –                        | –                        | –             | [59]            |
| SORT1-/-                   | Mice           | Knockout of SORT1 gene | HCD        | ↓                   | ↓                  | –                        | –                        | ↓             | [61]            |
| SORT1-/-; Patients with coronary artery disease | Human          | Aspirin         | –          | ↓                   | ↓                  | –                        | –                        | –             | [65]            |
| Patients with coronary artery disease | Human          | Non-statin      | –          | ↑                   | ↑                  | –                        | –                        | –             | [66]            |
| Patients with coronary artery disease | Human          | Statin          | –          | ↑                   | ↑                  | –                        | –                        | –             | [67]            |

ApoB: apolipoprotein B; LDL: low density lipoprotein; SNPs: single nucleotide polymorphisms; HCD: high cholesterol/cholate atherogenic diet; AAV: adeno-associated virus; AV: adenovirus; CHO: Chinese hamster ovary; WT: wide type; LDLR: low-density lipoprotein receptor; ↑: increased; ↓: decreased; -: non-observed results.
Nonetheless, increasing results demonstrated that over-expression of \textit{SORT1} lowered circulating lipid levels. One of the most interesting researches conducted by Musunuru et al. revealed that the hepatocyte with over-expression of \textit{SORT1} gene presented lower VLDL secretion rate through transporting VLDL to the lysosome, leading to reduced serum levels of cholesterol. Consequently, this result indicates a negative modulatory effect of sortilin in controlling intracellular lipid metabolism. Moreover, the authors also found that over-expression of \textit{SORT1} gene in hepatocyte could induce the decreased Apo-B100 synthesis, putting forward a novel pathway of sortilin in suppressing VLDL production and release through, at least partly, binding to Apo-B100 within Golgi apparatus [32].

More recently, an independent study suggested an interesting function for sortilin as an alternative LDLR in the liver. According to this suggestion, we could speculate that sortilin may increase the LDL endocytosis into hepatocytes and enhance the clearance of lipoprotein from circulation [47,60]. Conclusively, these potential mechanisms could propose that sortilin modulates both serum and intracellular lipid levels within hepatocytes. The mechanism is shown in Figure 1.

The discordant results mentioned above provide contradictory functions of sortilin on serum levels of VLDL-C which are probably induced by the diverse experimental mouse models. Otherwise, it still remains to be further explored whether the alteration of \textit{SORT1} gene expression results in dyslipidemia and its related metabolic diseases.

\section*{Adipocyte}

Overweight and obesity have been shown to be strongly associated with multiple chronic diseases, including dyslipidemia, hypertension, and type 2 diabetes mellitus [61,62]. At present, obesity is being identified as one of the most vital risk factors of cardio-metabolic syndrome, which resultanty induces the most common cause of death [63]. With in-depth research, it is being elucidated that one of the hallmarks of obesity is excessive storage of TG within the adipocyte that is the predominant cell type of adipose tissue. At present, the adipocyte is considered to be not only a huge repository of fat but also an essential source of adipocytokines [64,65]. Under obese condition, the adipocyte is hypertrophic and is involved in regulating serum lipid metabolism. Consistent with this notion, increasing results revealed that the adipose tissue contained such abundant adipose-derived mesenchymal stem cells (AMSCs) which could differentiate into mature adipocytes [66]. As is known to us, the differentiation process of AMSCs is separated into about three stage, as the early, the intermediate, and the terminal stage, hand in hand with a complex transcription factors, such as C/EBP\textsubscript{α/β} and proliferator activated receptor \textsubscript{γ}. To be more specific, C/EBP\textsubscript{β} embraces an essential function during adipocyte differentiation at the early stage [67], which subsequently stimulates the expression of C/EBP\textsubscript{α} within the intermediate stage [68]. Notably, the up-regulated C/EBP\textsubscript{α} could further lead to the transcription of numerous adipogenic differentiation related biomarkers, such as FABP-4 and fatty acid synthetase, and could maintain mature phenotype of adipocyte in the terminal stage [69]. Thereby, the aberrant adipogenic differentiation of AMSCs induces hyperplasia and hypertrophy of adipocytes, resultantly facilitating the pathological process of cardiometabolic disorder diseases.

The important functions of sortilin in modulating lipid catabolism within an adipocyte are gaining substantial appreciation since the adipocyte could produce and release multiple lipid metabolic-related proteins. The first results which

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure1.png}
\caption{Mechanisms whereby sortilin influences lipid metabolism in hepatocytes. Sortilin could promote VDL lipolysis by interacting with apolipoprotein B-100 and resultantly increasing circulating levels of LDL-C. LDLR: low-density lipoprotein receptor; Apo-B100: apolipoprotein B100; LDL: low-density lipoprotein; VLDL: very low-density lipoprotein; PCSK9: proprotein convertase subtilisin/kexin type 9.}
\end{figure}
showed an association between sortilin with the adipogenic differentiation of pre-adipocytes was reported by Breitling et al., who confirmed that expression content of SORT1 gene was increased significantly with the progression of adipogenesis. Some SNPs of SORT1 gene has been well-demonstrated to elucidate the functions of sortilin in controlling adipocytic lipid catabolism. For instance, the SNP of rs599839, which was shown previously to affect serum concentrations of LDL-C, played an important role in controlling adipogenesis [70]. Consistent with these findings, another study used SV129/BL6 mice and found that sortilin down-regulated the TG concentration within 3T3-L1 preadipocytes and suppressed the adipogenic differentiation via binding to a vital surface receptor, named the adipogenic limiting receptor δ-like protein 1 (DLK1) [71]. According to the previous reports, DLK1 has been found to be only expressed on the surface of pre-adipocytes and is being considered as a pre-adipocyte marker [72,73]. It has been well-established through in vitro and in vivo investigations that altered contents of DLK1 influence the process of adipogenesis [74]. Eye-caughtingly, increasing evidence has uncovered that DLK1 could be activated as an active soluble type via cleavage process induced by tumor necrosis factor α-converting enzyme (TACE). The active type of DLK1 was further verified to be a biomarker for adipocytic progenitors which suppress adipogenic differentiation [75]. Silencing DLK1 expression within 3T3-L1 pre-adipocyte mediates increased expression of C/EBPβ and C/EBPα, however, the combination of sortilin and DLK1 inhibit the degradation of DLK1 which consequently suppresses the adipogenic differentiation [76,77]. It is shown that sortilin inhibits the adipogenic progression of 3T3-L1 preadipocytes, presenting lower intracellular levels of C/EBPβ, C/EBPα, and TG contents. In conclusion, the results indicate that sortilin embraces the property of inhibiting adipogenic differentiation of pre-adipocyte [71].

Furthermore, results of another research provide a new function of sortilin in lipid homeostasis within adipocytes, which may make sortilin a therapeutic target for cardiometabolic disorders. In details, the authors used the LDLR/SORT1-DKO mice and confirmed that knockout of SORT1 gene inhibited the mRNA expression of Niemann-Pick type C1-Like 1 (NPC1L1) gene and further reduced the mass of white adipose tissue; synchronously, knockout of SORT1 gene brought improved function of brown adipose tissue through down-regulated expression of Kruppel-like factor 4 (KLF4) gene and liver X receptor (LXR) gene. In addition, those mice that were fed with a high cholesterol diet (HCD) presented increasing circulating levels of adiponectin [51]. Given that adiponectin is one of the most important adipokine which is negatively associated with the process of adipogenic differentiation [78,79], we could make a reasonable speculation that sortilin affect adipogenic differentiation via, at least partly, influencing adiponectin and subsequently inhibiting the development of cardiometabolic diseases through modulating the expression of NPC1L1 gene, KLF4 gene, and LXR gene.

At present, obesity and diabetes mellitus has been shown to be synergistically correlated with impaired glucose metabolism within adipocytes, which is induced by the decreased intracellular expression levels of glucose transporter 4 (GLUT4) [80-82]. Indeed, within the 3T3-L1 preadipocyte, SORT1 gene is a component of GLUT4 vesicles [83,84]. Otherwise, another independent experimental investigation demonstrated that administration of phosphatidylinositol 3-kinase (PI3K) inhibitors could reduce expression levels of sortilin protein but not SORT1 gene within adipocytes isolated from the chow-fed mice. The serum-starvation or suppression of the PI3K/AKT signaling pathway also reduced sortilin protein without altering SORT1 gene expression level within 3T3-L1 preadipocyte, suggesting that the PI3K/AKT signaling pathway may induce dynamically reduced levels of sortilin and affect the intracellular lipid catabolism through DLK1 [85]. Two other independent researches indicated that, under obese condition, mice with SORT1 gene deficiency present reduced serum TG content and increased uptake of glucose. This metabolic phenotype of adipocytes was further confirmed to be induced by decreased acid sphingomyelinase activity [86,87]. The comprehensive intracellular function of sortilin in lipid metabolism within adipocytes is shown in Figure 2.

Macrophage

Macrophages, as one of an important type of white blood cells, have been demonstrated to engulf intracellular debris, cancer cells, and anything that has not proteins specific to healthy cells [88]. Aside from the function in modulating systemic inflammatory response, it is also well-demonstrated that macrophage also holds an important function in maintaining the circulating cholesterol homeostasis [89]. Under the condition of dyslipidemia, macrophage could ingest LDL-C and subsequently form the foam cells by special surface receptors, such as LDL receptor, cluster of differentiation 36, and scavenger receptor A. After this vital step, the foam cell is intruded into the sub-endothelial zone and facilitates the atherosclerotic lesions [90]. Besides, macrophage has also been verified to remove excessive intracellular LDL-C through a classical pathway named reverse cholesterol transport by the ATP-binding cassette transporter A1 (ABCA1), ATP-binding cassette transporter G1 (ABCG1), and the scavenger receptor B1 (SR-B1) [91].

Recently, SORT1 gene has also been identified to be expressed in macrophage. Evidence from previous clinical trials has strongly suggested a vital regulatory effect of
sortilin in modulating the process of atherosclerosis through inducing foam cells formation, which reveals a relationship between sortilin and lipid metabolism within macrophage. For instance, an independent study already demonstrated the function of sortilin in modulating LDL uptake and foam cell formation. Besides, the authors also demonstrated that an Apobec1(-/-);hAPOB transgenic mice with SORT1-deficiency present no effect on regulating serum LDL-C levels, whereas with dramatically reduced atherosclerotic plaque areas within aortic root. Similarly, the SORT1/LDLR-DKO mice displayed reduced atherosclerotic plaque areas without any alteration in circulating levels of LDL-C, revealing that the recruitment of macrophage might not be the only mechanism whereby sortilin regulates the process of atherosclerosis [44]. As a consequence, the most possible mechanism might be that over-expressed SORT1 gene within macrophage could affect the LDL-C endocytosis. Notably, the author also observed that macrophage with SORT1-deficiency embraces protective function which inhibited the process of atherosclerosis through suppressed LDL-C uptake and foam cells formation within macrophage [44], indicating a new mechanism of sortilin in regulating the intercellular lipid metabolism aside from the traditional endocytosis of LDL-C in macrophages, such as via the LDLR or via the macropinocytosis.

The potential mechanisms whereby sortilin modulates the impaired cholesterol efflux from macrophage has been given substantial attention during the past several decades. According to the published reports, one of the main viewpoints is that the process of endocytosis of LDL particle induced by sortilin within macrophage might depend on serum concentrations of LDL-C. Under the condition of dyslipidemia, the exposure of macrophage to circulating LDL-C results in increased expression of SORT1 gene and sortilin protein within macrophage. Subsequently, this process may induce an increased LDL-C endocytosis by sortilin [92]. Otherwise, the other viewpoint might be that over-expression of SORT1 gene in macrophage up-regulates the content of sortilin protein, which could act as an intracellular sorting receptor and convey the lipid efflux transporters, such as ABCA1, ABCG1, and SR-B1, into the lysosome for subsequent degradation. In addition, this step leads to a significant reduction of lipid efflux mediated by macrophage [93]. Nonetheless, the precise mechanisms whereby sortilin affect intracellular lipid metabolism within macrophage need further investigation (Figure 3).

Conclusively, the underlying mechanisms whereby sortilin regulates serum or intra-cellular lipid metabolism within macrophage have been relatively elucidated. The sortilin level in macrophage has a close relationship with intercellular lipid metabolism and the inhibition of cholesterol efflux. Thereby, with excessive lipid storage within macrophage, sortilin facilitates the formation process of macrophage-derived foam cells and consequently promotes the pathological progression of atherosclerosis and its related coronary artery diseases.

ROLE OF SORTILIN IN MODULATING SERUM GLUCOSE METABOLISM

In addition to the significant functions in influencing the serum or intra-cellular lipid catabolism, various glucose-regulatory effects have been also ascribed to sortilin. According to the emerging technological breakthroughs, several underlying potential mechanisms by which sortilin influence the serum
glucose metabolism is being well-elucidated. As extensively shown in the previous studies, sortilin and GLUT4, as the most important transporter for glucose metabolism, are co-expressed within the adipocytes and myotubes, which have been demonstrated to be necessary for glucose accumulation \[94\]. Concerning this notion, fine-tuning of the expression contents of sortilin and myotubes are considered to be essential to maintain the insulin-induced intracellular transport of glucose. For instance, several research studies have shown that the formation of GLUT4-accumulated vesicles within the adipocyte and skeletal muscle cells was closely associated with the gene expression content of \(\text{SORT1}\) \[82,95\]. Moreover, the insulin-mediated translocation of GLUT4 has also been shown to be strongly correlated with the gene expression contents of \(\text{SORT1}\) within the adipocyte \[81\]. Concerning this notion, it has been speculated that the disrupted transport of glucose which was promoted by the pathogenic progression of insulin resistance under the condition of cardiometabolic syndrome, was associated with the alteration of the expression contents of sortilin \[96\].

On the other hand, the gene expression content of \(\text{SORT1}\) has also been shown to be reduced under multiple pathological statuses, such as diabetes mellitus, hypertension, and obesity. This significant inhibition has been further confirmed to be mediated by several pro-inflammatory cytokines, including TNF-\(\alpha\). Intriguingly, Kaddai et al. have postulated a potential relationship between the chronic inflammatory response, the serum sortilin concentrations, and the risk of diabetes mellitus \[96\]. Actually, the serum expression levels of sortilin are significantly altered in the mouse models with insulin resistance promoted by TNF-\(\alpha\) or the intervention of dexamethasone. Consistent with this result, in presence of TNF-\(\alpha\), the expression of \(\text{SORT1}\) gene was confirmed to be significantly reduced and could be closely correlated with insulin resistance. Nonetheless, on the contrary, the dexamethasone-mediated insulin resistance is shown to be not accompanied by the reduced gene expression contents of \(\text{SORT1}\) \[97,98\].

With in-depth investigations, the expression of \(\text{SORT1}\) gene was confirmed to be significantly reduced within adipocytes isolated from the obese mice, especially after the PI3K/AKT signaling pathway is inhibited, indicating that the insulin-dependent signal pathway could modulate the expression of sortilin \[99\]. In addition, it has been shown that both TNF-\(\alpha\) and dexamethasone could significantly inhibit the biological activity of insulin receptor tyrosine kinase, which subsequently facilitated the insulin resistance without influencing the translocation of GLUT4 \[100,101\]. Taken together, the results mentioned above indicate that the reduced expression of \(\text{SORT1}\) gene could be identified as one of the most important biomarkers which results in insulin resistance.

**CONCLUSION**

As described above, there is considerable evidence linking the significant variability at the \(\text{SORT1}\) gene locus with the increased risk of dyslipidemia and its related cardio-metabolic syndrome. Though the potential mechanism is needed to be further elucidated, it is reasonable to make a speculation to conclude that the relationships between higher serum levels of LDL-C is closely correlated with the \(\text{SORT1}\) SNPs in patients worldwide. On the other hand, almost all the published results...
provided an unequivocal function of SORT1 SNPs in regulating lipid metabolism, shedding light on that the effect of 1p13.3 gene locus could be identified as a novel biomarker representing the risk of dyslipidemia and its related cardiometabolic syndrome, such as overweight/obesity, atherosclerotic coronary diseases, and diabetes mellitus. Aside from the regulatory role of SORT1 gene SNPs, the expression of sortilin in hepatocyte, adipocyte, and macrophage indicates that sortilin could be considered as an essential factor in controlling intracellular lipid catabolism and resultantly influences the pathological process of cardiometabolic syndrome.

Although multiple breakthroughs have been provided to deeply elucidate the relationship between the alterations of circulating sortilin and the risk of dyslipidemia due to the technological advances, some reports verified the contradictory effect of over-expressed SORT1 gene on modulating the circulating level of LDL-C. To date, the accurate biological function of sortilin seem to be clarified, it is still worth noting that the effect of sortilin in regulating circulating and intercellular lipid catabolism is controversial. We need large-scale and more comprehensive study to further elucidate the modulatory function of sortilin within hepatocyte, adipocyte, and macrophage.

REFERENCES

[1] Su X, Peng DQ. New insights into ANGPT1 in controlling lipoprotein metabolism and risk of cardiovascular diseases. Lipids Health Dis 2018;17(1):122.
[2] Brown WV. Clinical lipolysis and the prevention of vascular disease: Time for personalized therapy. Clin Pharmacol Ther 2018;104(2):269-81.
[3] Demignot S, Beilstein F, Morel E. Triglyceride-rich lipoproteins and cytosolic lipid droplets in enterocytes: Key players in intestinal physiology and metabolic disorders. Biochimie 2014;96:48-55.
[4] Shirai K. Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Curr Med Res Opin 2018;42(3):295-304.
[5] Contois JH, McConnell JP, Sethi AA, Csako G, Devaraj S, Hoefner DM, et al. Apolipoprotein B and cardiovascular disease risk: Position statement from the AACC lipoproteins and vascular diseases division working group on best practices. Clin Chem 2009;55(3):407-19.
[6] Cziraky MJ, Watson KE, Talbert RT. Targeting Low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manage Care Pharm 2009;15(1):Suppl 8:S1-28; quiz S30-1.
[7] Rana JS, Bockholdt SM, Kastelein JJ, Shah PK. The role of non-HDL cholesterol in risk stratification for coronary artery disease. Curr Atheroscler Rep 2012;14(4):130-4.
[8] Liakopoulos OJ, Kuhn EW, Sottoschi I, Thielmann M, Wendt D, Kuh K, et al. Statin therapy in patients undergoing coronary artery bypass grafting for acute coronary syndrome. Thorac Cardiovasc Surg 2018;66(6):434-41.
[9] Goettsch C, Kjolby M, Aikawa E. Sortilin and its multiple roles in cardiovascular and metabolic diseases. Arterioscler Thromb Vasc Biol 2018;38(1):19-25.
[10] Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008;40(2):161-9.
[11] Kathiresan S, Malmberg O, Giuducci C, Sarti A, Burtt NP, Riedl MJ, et al. Six new loci associated with low blood-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008;40(2):189-97.
[12] Kjolby M, Andersen OM, Breiderhoff T, Fjorback AW, Pedersen KM, Madsen P, et al. Sortilin, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export. Cell Metab 2010;12(3):213-23.
[13] Felisky D, Szeszko P, Yu L, Honer WG, De Jager PL, Schneider JA, et al. The SORL1 gene and convergent neural risk for Alzheimer's disease across the human lifespan. Mol Psychiatry 2014;19(10):1125-32.
[14] Faulkner S, Roselli S, Thorne RF, Scarlett CJ, Walker MM, Hondermark H. Prong and sortilin expression and function in pancreatic cancer. Asia-Pac J Clin Oncol 2014;10:121.
[15] Strong A, Patel K, Rader DJ. Sortilin and lipoprotein metabolism: Making sense out of complexity. Curr Opin Lipidol 2014;25(3):350-7.
[16] Yang W, Wu PF, Ma JX, Liao MJ, Wang XH, Xu LS, et al. Sortilin promotes glioblastoma invasion and mesenchymal transition through GSK-3 beta-beta-catenin/twist pathway. Cell Death Dis 2019;10(3):208.
[17] Kebede MA, Oler AT, Gregg T, Balloon AJ, Johnson A, Mitok K, et al. SORCS1 is necessary for normal insulin secretory granule biogenesis in metabolically stressed beta cells. J Clin Invest 2014;124(10):4240-53.
[18] Duhe JB, Johansen CT, Hegde RA. Sortilin: An unusual suspect in cholesterol metabolism: From GWAS identification to in vivo biochemical analyses, sortilin has been identified as a novel mediator of human lipoprotein metabolism. BioEssays 2015;37(6):430-7.
[19] Pallesen LT, Vaegter CB. Sortilin and SorLA regulate neuronal sorting of trophic and dementia-linked proteins. Mol Neurobiol 2014;48(2):350-7.
[20] Zollo A, Allen Z, Rasmussen HF, Iannuzzi F, Shi Y, Larsen A, et al. Sortilin-related receptor expression in human neural stem cells and more comprehensive study to further elucidate the modulatory function of sortilin within hepatocyte, adipocyte, and macrophage.

Bosn J Basic Med Sci. 2022;22(3):340-352

Goettsch C, Kjolby M, Aikawa E. Sortilin and its multiple roles in cardiovascular and metabolic diseases. Arterioscler Thromb Vasc Biol 2018;38(1):19-25.

https://doi.org/10.1161/ATVBAHA.117.310292

Wi...
Su et al.: Role of sortilin in glucose metabolism and lipid profiles

Alzheimer’s disease in the Chinese Han population. Neuroreport 2013;24(1):464-8. https://doi.org/10.1016/j.wnr.2013.02.069

Feng Q, Wei WQ, Levinson RT, Mosley JD, Stein CM. Replication and fine-mapping of genetic predictors of lipids traits in African-Americans. J Hum Genet 2017;62(10):895-901. https://doi.org/10.1038/jhg.2017.55

Strong A, Rader DJ. Sortilin as a regulator of lipoprotein metabolism. Curr Atheroscler Rep 2012;14(3):211-8. https://doi.org/10.1007/s11883-012-0248-x

Strong A, Ding Q, Edmondson AC, Miller JS, Sachs KV, Li X, et al. Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J Clin Invest 2012;122(8):2807-16. https://doi.org/10.1172/JCI63503

Ai D, Baez JM, Jiang H, Conlon DM, Hernandez-Ono A, Frank-Kamenetsky M, et al. Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice. J Clin Invest 2012;122(5):1677-87. https://doi.org/10.1172/JCI4248

Patel KM, Strong A, Tohyama J, Lin X, Morales CR, Billheimer J, et al. Macrophage sortilin regulates LDL uptake and foam cell formation, and atherosclerosis. Circ Res 2015;116(5):789-96. https://doi.org/10.1161/CIRCRESAHA.116.305811

Kjolby M, Nielsen MS, Petersen CM. Sortilin, encoded by the cardiovasculard gene SORT1, and its suggested functions in cardiovascular disease. Curr Atheroscler Rep 2013;15(3):496. https://doi.org/10.1007/s11883-013-0496-7

Gustafsson C, Kjolby M, Nygaard M, Mattheisen M, Lundhede J, Buttenschon H, et al. The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion. Cell Metab 2014;19(2):310-8. https://doi.org/10.1016/j.cmet.2013.12.006

Linsel-Nitschke P, Heeren J, Aherrahrouz H, Bruse P, Gieger C, Illig T, et al. Genetic variation at chromosome 1p33.3 affects sortilin mRNA expression, cellular LDL-uptake and serum LDL levels which translates to the risk of coronary artery disease. Atherosclerosis 2010;210(1):183-9. https://doi.org/10.1016/j.atherosclerosis.2009.06.034

Rabinowich L, Ishman S, Hubel E, Thurun T, Park WJ, Prewzner-Jung Y, et al. Sortilin deficiency improves the metabolic phenotype and reduces hepatic steatosis of mice subjected to diet-induced obesity. J Hepatol 2015;62(1):175-81. https://doi.org/10.1016/j.jhep.2014.08.030

Tveten K, Strom TB, Cameron J, Berge KP, Kuller H, et al. Mutations in the SORT1 gene are unlikely to cause autosomal dominant hypercholesterolemia. Atherosclerosis 2012;225(2):370-5. https://doi.org/10.1016/j.atherosclerosis.2012.10.026

Mortensen MB, Kjolby M, Gunnerson S, Larsen JV, palmfeldt J, Falk E, et al. Targeting sortilin in immune cells reduces proinflammatory cytokines and atherosclerosis. J Clin Invest 2014;124(9):3537-22. https://doi.org/10.1172/JCI69002

Hayata S, Rogers MA, Pham T, Wen JR, Mlynarchik AK, Aikawa M, et al. Transcriptional control of intestinal cholesterol absorption, adipose energy expenditure and lipid handling by Sortilin. Sci Rep 2018:8(1):9006. https://doi.org/10.1038/s41598-018-27416-y

Ogawa K, Ueno T, Iwasaki T, Kujiraoka T, Ishihara M, Kunimoto S, et al. Soluble sortilin is released by activated platelets and its circulating levels are associated with cardiovascular risk factors. Atherosclerosis 2016;249:110-5. https://doi.org/10.1016/j.atherosclerosis.2016.03.041

Hu D, Yang Y, Peng DQ. Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease. Int J Cardiol 2017;227:61-5. https://doi.org/10.1016/j.ijcard.2016.11.064

Cai Z, Mei K, Ai Q. Regulation of hepatic lipid deposition by phosholipid in large yellow croaker Br J Nutr 2017;118(12):1999-1009. https://doi.org/10.1017/s000711451700294X

Leibing T, Geraud C, Augustin I, Boutros M, Augustin H, Okun JG, et al. Angiocrine Wnt signaling controls liver growth and
metabolic maturation in mice. Hepatology 2018;68(2):707-22.
https://doi.org/10.1002/hep.26613

[56] Cocci P, Mosconi G, Palermo FA. Changes in expression of microRNA potentially targeting key regulators of lipid metabolism in primary gilthead sea bream hepatocytes exposed to phthalates or flame retardants. Aquat Toxicol 2019;209:81-90.
https://doi.org/10.1016/j.aquatox.2019.02.002

[57] Qiao JT, Cui C, Qiang L, Wang LS, He TY, Yan F, et al. Activation of the STING-IRF3 pathway promotes hepatocyte inflammation, apoptosis and induces metabolic disorders in nonalcoholic fatty liver disease. Metabolism 2018;81:13-24.
https://doi.org/10.1016/j.metabol.2017.09.010

[58] Patel RS, Scopelliti EM, Oughlile O. The role of PCSK9 inhibitors in the treatment of hypercholesterolemia. Ann Pharmacother 2018;52(10):1000-18.
https://doi.org/10.1177/1078683618771670

[59] Chen C, Li J, Matye DJ, Wang Y, Li T. Hepatocyte sortilin 1 knockout and treatment with a sortilin 1 inhibitor reduced plasma cholesterol in Western diet-fed mice. J Lipid Res 2019;60(3):539-49.
https://doi.org/10.1194/jlr.M097989

[60] Linsel-Nitschke P, Samani NJ, Schunkert H. Sorting out cholesterol and coronary artery disease. N Engl J Med 2010;363(25):2492-3.
https://doi.org/10.1056/NEJMci1001765

[61] Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav 2008;94(2):206-18.
https://doi.org/10.1016/j.physbeh.2007.10.010

[62] Engin AB. Adipocyte-macrophage cross-talk in obesity. Adv Exp Med Biol 2017;960:327-43.
https://doi.org/10.1007/978-3-319-48382-5_14

[63] Ryder M, Andersson DP, Bernard S, Spalding K, Arner P. Adipocyte triglyceride turnover and lipolysis in lean and overweight subjects. J Lipid Res 2013;54(10):2909-13.
https://doi.org/10.1194/jlr.M031945

[64] Versini M, Jeandel PY, Gomes C, Brun E, Duthoit E, Pannier B, et al. Insulin resistance induces posttranslational modification of the PPARalpha signaling pathway. PLoS One 2017;12(9):e0184949.
https://doi.org/10.1371/journal.pone.0184949

[65] Johnston A, Arnadottir S, Gudjonsson JE, Aphale A, Shoenfeld Y. Obesity in autoimmune diseases: Not a passive bystander. Autoimmun Rev 2010;9(8):809-16.
https://doi.org/10.1016/j.autrev.2011.07.001

[66] Johnstone A, Armadotter S, Gudjonsson JE, Aplaha F, Sigmarsdottir AA, Gunnarsson SI, et al. Obesity in psoriasis: Leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 2010;163(3):599-1000.
https://doi.org/10.1111/j.1365-2133.2010.09212.x

[67] Zhu KJ, Shi G, Zhang C, Li M, Zhu CY, Fan YM. Adiponectin levels in patients with psoriasis: A meta-analysis. J Dermatol 2013;40(6):438-42.
https://doi.org/10.1111/1346-8138.12121

[68] Shibata S, Tada H, Hau CS, Mitsui A, Kamata M, Asano Y, et al. Adiponectin regulates psoriasis skin inflammation by suppressing IL-17 production from gamma-delta T-cells. Nat Commun 2015;6:7887.
https://doi.org/10.1038/ncomms8867

[69] Tsuchiya Y, Hatakeyama H, Emoto N, Wagatsuma F, Matsushita S, Kanazaki M. Palmitate-induced down-regulation of sortilin and impaired GLUT4 trafficking in C2C12 myotubes. J Biol Chem 2010;285(14):34371-81.
https://doi.org/10.1074/jbc.M110.128520

[70] Huang G, Buckler-Pena D, Nauta T, Singh M, Asmar A, Shi J, et al. Insulin responsiveness of glucose transporter 4 in 3T3-L1 cells depends on the presence of sortilin. Mol Biol Cell 2013;24(19):3115-22.
https://doi.org/10.1091/mbc.E12-10-0765

[71] Ariga M, Yoneyama Y, Fukushima T, Ishiuchi Y, Ishii T, Sato H, et al. SIRT1 regulates GLUT4 expression in the PPARalpha signaling pathway. Mol Biol Cell 2013;24(19):3115-22.
https://doi.org/10.1091/mbc.E12-10-0765

[72] Tsuchiya Y, Hatakeyama H, Emoto N, Wagatsuma F, Matsushita S, Kanazaki M. Palmitate-induced down-regulation of sortilin and impaired GLUT4 trafficking in C2C12 myotubes. J Biol Chem 2010;285(14):34371-81.
https://doi.org/10.1074/jbc.M110.128520

[73] Shi J, Kovacs SI, Wang Y, Ludden TM, Bhargava VO. Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis. J Pharmacokinet Pharmacodyn 2005;32(3-4):419-39.
https://doi.org/10.1007/s10928-005-0049-8

[74] Rubin BR, Bogan JS. Intracellular retention and insulin-stimulated mobilization of GLUT4 glucose transporters. Vitam Horm 2009;80:155-92.
https://doi.org/10.1016/S0083-6729(08)00653-X

[75] Zhao SP, Li R, Dai W, Yu BL, Chen LZ, Huang XS. Xuezhikang and treatment with a sortilin 1 inhibitor reduced plasma cholesterol in the treatment of hypercholesterolemia. Biol Rev Camb Philos Soc 2014;90(2):3477-87.
https://doi.org/10.1016/j.bbr.2013.05.004

[76] Sul HS. Minireview: Pref-1: Role in adipogenesis and mesenchymal cell fate. Mol Endocrinol 2009;23(11):1717-25.
https://doi.org/10.1210/me.2009-0610

[77] Hudak CS, Gulyaeva O, Wang Y, Park SM, Lee L, Kang C, et al. Pref-1 marks very early mesenchymal precursors required for adipose tissue development and expansion. Cell Rep 2014;8(3):678-87.
https://doi.org/10.1016/j.celrep.2014.06.060

[78] Zheng XY, Yu BL, Chen LZ, Huang XS. Pref-1 contributes to greater triglyceride reduction than simvastatin in hypertriglyceridemia rats by up-regulating apolipoprotein A5 via ROCK-dependent inhibition of 3T3-L1 adipogenesis by G-protein-deamidating dromocoric toxins: Differential regulation of Notchi, Pref-1/Dlk1, and beta-catenin signaling. Front Cell Infect Microbiol 2012;2:80.
https://doi.org/10.3389/fcimb.2012.00080

[79] Zhou KJ, Shi G, Zhang C, Li M, Zhu CY, Fan YM. Adiponectin levels in patients with psoriasis: A meta-analysis. J Dermatol 2013;40(6):438-42.
https://doi.org/10.1111/1346-8138.12121
Su et al.: Role of sortilin in glucose metabolism and lipid profiles

3T3-L1 adipocytes. J Biol Chem 2014;289(1):133-42. https://doi.org/10.1074/jbc.M113.532440

[88] Wang N, Li JY, Li S, Guo XC, Wu T, Wang WF, et al. Fibroblast growth factor 21 regulates foam cells formation and inflammatory response in Ox-LDL-induced THP-1 macrophages. Biomed Pharmacother 2018;108:1825-34. https://doi.org/10.1016/j.biopha.2018.09.143

[89] Jin P, Bian Y, Wang K, Cong G, Yan R, Sha Y, et al. Homocysteine accelerates atherosclerosis via inhibiting LXalpha1-dependent cholesterol efflux from macrophages. Life Sci 2018;214:41-50. https://doi.org/10.1016/j.lfs.2018.10.060

[90] Anzinger Jl, Chang J, Xu Q, Barthwal MK, Bohnacker T, Wymann MP, et al. Murine bone marrow-derived macrophages differentiated with GM-CSF become foam cells by PI3Kgamma-dependent fluid-phase pinocytosis of native LDL. J Lipid Res 2012;53(1):34-42. https://doi.org/10.1194/jlr.M018887

[91] Barthwal MK, Anzinger Jl, Xu Q, Bohnacker T, Wymann MP, Kruth HS. Fluid-phase pinocytosis of native low density lipoprotein promotes murine M-CSF differentiated macrophage foam cell formation. PLoS One 2013;8(3):e58054. https://doi.org/10.1371/journal.pone.0058054

[92] Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stynanou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010;466(7307):707-13. https://doi.org/10.1038/nature09270

[93] Willnow TE, Kjolby M, Nykjaer A. Sortilins: New players in lipoprotein metabolism. Curr Opin Lipidol 2011;22(2):79-85. https://doi.org/10.1097/MOL.0b013e328341f6db

[94] Bogan JS, Kandror KV. Biogenesis and regulation of insulin-responsive vesicles containing GLUT4. Curr Opin Cell Biol 2010;22(4):506-12. https://doi.org/10.1016/j.jcb.2010.03.012

[95] Ariga M, Nedachi T, Katagiri H, Kanzaki M. Functional role of sortilin in myogenesis and development of insulin-responsive glucose transport system in C2C12 myocytes. J Biol Chem 2008;283(15):10208-20. https://doi.org/10.1074/jbc.M710604200

[96] Kaddai V, Jager J, Gonzalez T, Najem-Lendom R, Bonnafous S, Tran A, et al. Involvement of TNF-alpha in abnormal adipocyte and muscle sortilin expression in obese mice and humans. Diabetologia 2009;52(5):932-40. https://doi.org/10.1007/s00125-009-1773-3

[97] Hivelin C, Mazella J, Coppola T. Sortilin derived propeptide regulation during adipocyte differentiation and inflammation. Biochem Biophys Res Commun 2017;482(1):87-92. https://doi.org/10.1016/j.bbrc.2016.10.139

[98] Botten G, Collina F, Scognamiglio G, Rao F, Peluso V, De Cecio R, et al. Programmed death ligand 1 (PD-L1) tumor expression is associated with a better prognosis and diabetic disease in triple negative breast cancer patients. Int J Mol Sci 2017;18(2):459. https://doi.org/10.3390/ijms18020459

[99] Li J, Matye DJ, Wang Y, Li T. Sortilin 1 knockout alters basal adipose glucose metabolism but not diet-induced obesity in mice. FEBS Lett 2017;591(7):1018-28. https://doi.org/10.1002/1873-3468.12610

[100] Qi D, Pulinilkunnil T, An D, Ghosh S, Abrahani A, Pospisilik JA, et al. Single-dose doxazosin induces whole-body insulin resistance and alters both cardiac fatty acid and carbohydrate metabolism. Diabetes 2004;53(7):1790-7. https://doi.org/10.2337/diabetes.53.7.1790

[101] Rui L, Aguirre V, Kim JK, Shulman GI, Lee A, Corbould A, et al. Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest 2003;110(2):181-9. https://doi.org/10.1172/JCI10934

Related articles published in BJBMS

1. New insights into the pathological development of dyslipidemia in patients with hypothyroidism
   Xin Su et al., BJBMS, 2021